Aerie Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AERI Nasdaq 2834 http://www.aeriepharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan - Oct 12th, 2021 10:30 am
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase - Oct 7th, 2021 8:01 pm
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists - Oct 6th, 2021 11:30 am
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference - Sep 27th, 2021 11:30 am
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition - Sep 20th, 2021 10:30 am
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win - Sep 17th, 2021 11:40 am
56 Biggest Movers From Yesterday - Sep 17th, 2021 9:28 am
Why The Future Is Cloudy For This Aerie Pharmaceuticals Drug As Shares Plummet - Sep 16th, 2021 8:13 pm
Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge - Sep 16th, 2021 6:46 pm
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study - Sep 16th, 2021 3:19 pm
Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August - Sep 16th, 2021 2:20 pm
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial - Sep 16th, 2021 9:59 am
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease - Sep 15th, 2021 8:01 pm
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications - Sep 13th, 2021 10:30 am
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 7th, 2021 11:30 am
Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing - Sep 7th, 2021 10:30 am
Aerie (AERI) Down 0.9% Since Last Earnings Report: Can It Rebound? - Sep 3rd, 2021 3:31 pm
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference - Aug 12th, 2021 11:30 am
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat - Aug 5th, 2021 3:42 pm
Aerie Pharmaceuticals, inc (AERI) Q2 2021 Earnings Call Transcript - Aug 5th, 2021 3:31 am